Tecemotide: An antigen-specific cancer immunotherapy

Gregory T. Wurz, Chiao Jung Kao, Michael Wolf, Michael W. DeGregorio

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The identification of tumor-associated antigens (TAA) has made possible the development of antigen-specific cancer immunotherapies such as tecemotide. One of those is mucin 1 (MUC1), a cell membrane glycoprotein expressed on some epithelial tissues such as breast and lung. In cancer, MUC1 becomes overexpressed and aberrantly glycosylated, exposing the immunogenic tandem repeat units in the extracellular domain of MUC1. Designed to target tumor associated MUC1, tecemotide is being evaluated in Phase III clinical trials for treatment of unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC) as maintenance therapy following chemoradiotherapy. Additional Phase II studies in other indications are ongoing. This review discusses the preclinical and clinical development of tecemotide, ongoing preclinical studies of tecemotide in human MUC1 transgenic mouse models of breast and lung cancer, and the potential application of these models for optimizing the timing of chemoradiotherapy and tecemotide immunotherapy to achieve the best treatment outcome for patients.

Original languageEnglish (US)
Pages (from-to)3383-3393
Number of pages11
JournalHuman Vaccines and Immunotherapeutics
Volume10
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Mucin-1
Immunotherapy
Antigens
Chemoradiotherapy
Neoplasms
Phase III Clinical Trials
Tandem Repeat Sequences
Membrane Glycoproteins
Neoplasm Antigens
Non-Small Cell Lung Carcinoma
Transgenic Mice
Lung Neoplasms
Breast
Epithelium
Cell Membrane
L-BLP25
Breast Neoplasms
Lung
Therapeutics

Keywords

  • Chemoradiotherapy
  • Immunotherapy
  • MUC1
  • Non-small cell lung cancer
  • Tecemotide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Wurz, G. T., Kao, C. J., Wolf, M., & DeGregorio, M. W. (2014). Tecemotide: An antigen-specific cancer immunotherapy. Human Vaccines and Immunotherapeutics, 10(11), 3383-3393. https://doi.org/10.4161/hv.29836

Tecemotide : An antigen-specific cancer immunotherapy. / Wurz, Gregory T.; Kao, Chiao Jung; Wolf, Michael; DeGregorio, Michael W.

In: Human Vaccines and Immunotherapeutics, Vol. 10, No. 11, 01.11.2014, p. 3383-3393.

Research output: Contribution to journalArticle

Wurz, GT, Kao, CJ, Wolf, M & DeGregorio, MW 2014, 'Tecemotide: An antigen-specific cancer immunotherapy', Human Vaccines and Immunotherapeutics, vol. 10, no. 11, pp. 3383-3393. https://doi.org/10.4161/hv.29836
Wurz, Gregory T. ; Kao, Chiao Jung ; Wolf, Michael ; DeGregorio, Michael W. / Tecemotide : An antigen-specific cancer immunotherapy. In: Human Vaccines and Immunotherapeutics. 2014 ; Vol. 10, No. 11. pp. 3383-3393.
@article{b7ee1ce08530475996977ae15d7b6d10,
title = "Tecemotide: An antigen-specific cancer immunotherapy",
abstract = "The identification of tumor-associated antigens (TAA) has made possible the development of antigen-specific cancer immunotherapies such as tecemotide. One of those is mucin 1 (MUC1), a cell membrane glycoprotein expressed on some epithelial tissues such as breast and lung. In cancer, MUC1 becomes overexpressed and aberrantly glycosylated, exposing the immunogenic tandem repeat units in the extracellular domain of MUC1. Designed to target tumor associated MUC1, tecemotide is being evaluated in Phase III clinical trials for treatment of unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC) as maintenance therapy following chemoradiotherapy. Additional Phase II studies in other indications are ongoing. This review discusses the preclinical and clinical development of tecemotide, ongoing preclinical studies of tecemotide in human MUC1 transgenic mouse models of breast and lung cancer, and the potential application of these models for optimizing the timing of chemoradiotherapy and tecemotide immunotherapy to achieve the best treatment outcome for patients.",
keywords = "Chemoradiotherapy, Immunotherapy, MUC1, Non-small cell lung cancer, Tecemotide",
author = "Wurz, {Gregory T.} and Kao, {Chiao Jung} and Michael Wolf and DeGregorio, {Michael W.}",
year = "2014",
month = "11",
day = "1",
doi = "10.4161/hv.29836",
language = "English (US)",
volume = "10",
pages = "3383--3393",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - Tecemotide

T2 - An antigen-specific cancer immunotherapy

AU - Wurz, Gregory T.

AU - Kao, Chiao Jung

AU - Wolf, Michael

AU - DeGregorio, Michael W.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The identification of tumor-associated antigens (TAA) has made possible the development of antigen-specific cancer immunotherapies such as tecemotide. One of those is mucin 1 (MUC1), a cell membrane glycoprotein expressed on some epithelial tissues such as breast and lung. In cancer, MUC1 becomes overexpressed and aberrantly glycosylated, exposing the immunogenic tandem repeat units in the extracellular domain of MUC1. Designed to target tumor associated MUC1, tecemotide is being evaluated in Phase III clinical trials for treatment of unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC) as maintenance therapy following chemoradiotherapy. Additional Phase II studies in other indications are ongoing. This review discusses the preclinical and clinical development of tecemotide, ongoing preclinical studies of tecemotide in human MUC1 transgenic mouse models of breast and lung cancer, and the potential application of these models for optimizing the timing of chemoradiotherapy and tecemotide immunotherapy to achieve the best treatment outcome for patients.

AB - The identification of tumor-associated antigens (TAA) has made possible the development of antigen-specific cancer immunotherapies such as tecemotide. One of those is mucin 1 (MUC1), a cell membrane glycoprotein expressed on some epithelial tissues such as breast and lung. In cancer, MUC1 becomes overexpressed and aberrantly glycosylated, exposing the immunogenic tandem repeat units in the extracellular domain of MUC1. Designed to target tumor associated MUC1, tecemotide is being evaluated in Phase III clinical trials for treatment of unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC) as maintenance therapy following chemoradiotherapy. Additional Phase II studies in other indications are ongoing. This review discusses the preclinical and clinical development of tecemotide, ongoing preclinical studies of tecemotide in human MUC1 transgenic mouse models of breast and lung cancer, and the potential application of these models for optimizing the timing of chemoradiotherapy and tecemotide immunotherapy to achieve the best treatment outcome for patients.

KW - Chemoradiotherapy

KW - Immunotherapy

KW - MUC1

KW - Non-small cell lung cancer

KW - Tecemotide

UR - http://www.scopus.com/inward/record.url?scp=84921742575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921742575&partnerID=8YFLogxK

U2 - 10.4161/hv.29836

DO - 10.4161/hv.29836

M3 - Article

C2 - 25483673

AN - SCOPUS:84921742575

VL - 10

SP - 3383

EP - 3393

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 11

ER -